291533-77-2

Upstream product

• 98-61-3 p-Iodobenzenesulfonyl chloride 
• 4248-19-5 tert-butyl carbazate 
• 291534-50-4 (+/-)-methyl 2-(tert-butoxycarbonylamino)-5-phenylpent-4-ynoate 
• 70837-20-6 propargyclycine methyl ester hydrochloride 
• 71460-02-1 methyl 2-[((1,1-dimethylethoxy)carbonyl)amino]-4-pentynoate 

Downstream Products

• 291533-86-3 methyl 2-{[4'-thiomethoxy(1,1'-biphenyl)-4-yl]sulfonyl}amino-5-phenylpent-4-ynoate 
• 291533-87-4 Methyl 2-{[3',4'-Methylenedioxy-(1,1'-biphenyl)-4-yl]-sulfonyl}-amino-5-phenylpent-4-ynoate 
• 291533-92-1 methyl 2-[4-(4-Methoxyphenyl)-acetylenylbenzenesulfonyl]-amino-5-phenylpent-4-ynoate 
• 291533-91-0 5-phenyl-2-(4-p-tolylethynyl-benzenesulfonylamino)-pent-4-ynoic acid methyl ester 
• 291533-90-9 2-(3'-ethoxy-biphenyl-4-sulfonylamino)-5-phenyl-pent-4-ynoic acid methyl ester 
• 291533-85-2 5-phenyl-2-([1,1';4',1'']terphenyl-4-sulfonylamino)-pent-4-ynoic acid methyl ester 
• 291534-57-1 methyl 2-{[4'-methoxy-(1,1'-biphenyl)-4-yl]-sulfonyl}-amino-5-phenylpent-4-ynoate 
• 291533-75-0 methyl 2-{[4'-fluoro-(1,1'-biphenyl)-4-yl]-sulfonyl}-amino-5-phenylpent-4-ynoate 

Relevant academic research and scientific papers

Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines

A series of carboxylic acids were prepared from a propargylglycine scaffold and tested for efficacy as matrix metalloproteinase (MMP) inhibitors. Detailed SAR for the series is reported for four enzymes within the MMP family. The inhibitors were typically

Alkenyl- and alkynl-containing metalloprotease inhibitors

Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): where X, W, Z, A, G, R1, R2, R3, R4, R5, R5′and k have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof Also described are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.